FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib

BACKGROUND: Fibroblast growth factor receptor (FGFR) fusions in non-small cell lung cancer (NSCLC) are small genomic events. At present, there is no standard treatment strategy for patients with NSCLC carrying an FGFR fusion. CASE PRESENTATION: We report the case of a 45-year-old female patient who...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Chen, Wei, Jianping, Zhou, Tao, Wang, Xia, Cai, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196998/
https://www.ncbi.nlm.nih.gov/pubmed/35712652
http://dx.doi.org/10.2147/OTT.S364566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196998/
https://www.ncbi.nlm.nih.gov/pubmed/35712652
http://dx.doi.org/10.2147/OTT.S364566

Ejemplares similares